The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Mao, Yan ^a,b   Qu, Qing ^b   Chen, Xiaosong ^b   Huang, Ou ^b   Wu, Jiayi ^b   Shen, Kunwei ^b  

^a QINGDAO UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; ESTROGEN RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; FEMALE; IMMUNOLOGY; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS;

EID: 84963864205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152500     Document Type: Article

References (51)

1. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. (2013) Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 19: 28-33. doi: 10.1158/1078-0432.CCR-11-2701 PMID: 23258741
2. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in nodepositive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31: 860-867. doi: 10.1200/JCO.2011.41.0902 PMID: 23341518
3. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH,et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955. doi: 10. 1200/JCO.2010.30.5037 PMID: 21483002
4. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N,et al. (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3: 817-819. PMID: 9815754
5. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107: 864-873. doi: 10. 1038/bjc.2012.347 PMID: 22878371
6. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, De Wind A,et al. (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123: 2873-2892. doi: 10.1172/JCI67428 PMID: 23778140
7. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391. PMID: 16106245
8. Hayes DF, Ethier S, Lippman ME. (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100: 237-238. PMID: 16773436
9. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. (2007) Practical methods for incorporating summary time-to-event data into meta-analysis.Trials 8:16. PMID: 17555582
10. De Graeff P, Crijns AP, De Jong S, Boezen M, Post WJ, De Vries EG, et al. (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: A meta-analysis. Br J Cancer 101(1): 149-159. doi: 10.1038/sj.bjc.6605112 PMID: 19513073
11. Adams S, Gray R, Demaria S, Goldstein L, Perez EA, Shulman LN,et al. (2014) Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959-66. PMID: 25071121
12. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D,et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25(8):1544-1550. doi: 10.1093/annonc/mdu112 PMID: 24608200
13. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. (2013) The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 109: 1676-1684. doi: 10.1038/bjc.2013.493 PMID: 23982600
14. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M,et al. (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 25: 1536-1543. doi: 10. 1093/annonc/mdu191 PMID: 24915873
15. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58: 1107-1116. doi: 10.1111/j.1365-2559.2011.03846.x PMID: 21707712
16. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL,et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380. PMID: 17135638
17. Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X,et al. (2014) Intratumoral CD8(+) Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer. PLoS One 9(4):e95475. doi: 10.1371/journal.pone.0095475 PMID: 24743335
18. De Kruijf EM, Van Nes JGH, Sajet A, Tummers QR, Putter H, Osanto S,et al. (2010)The predictive value of HLA class I tumor cell expression and presence of intratumoral tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16: 1272-1280. doi: 10.1158/1078-0432.CCR-09-1844 PMID: 20145162
19. Kim S, Lee A, Lim W, Park S, Cho MS, Koo H, et al. (2014) Zonal difference and prognostic significance of FOXP3 regulatory T cell infiltration in breast cancer. J Breast Cancer 17: 8-17. doi: 10.4048/jbc. 2014.17.1.8 PMID: 24744792
20. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, et al. (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36: 224-231. doi: 10.1097/COC.0b013e3182467d90 PMID: 22495453
21. Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130: 645-655. doi: 10.1007/s10549-011-1647-3 PMID: 21717105
22. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14: R48. PMID: 22420471
23. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189: 5029-5036. doi: 10.4049/jimmunol. 1201892 PMID: 23034170
24. Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, et al. (2014) Expression of B7-H3, a Potential Factor of Tumor Immune Evasion in Combination with the Number of Regulatory T Cells, Affects Against Recurrence-Free Survival in Breast Cancer Patients. Ann Surg Oncol Feb 22 [Epub ahead of print]
25. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132: 545-553. doi: 10.1007/s10549-011-1620-1 PMID: 21671016
26. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, et al. (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127: 99-108. doi: 10.1007/s10549-010-0987-8 PMID: 20556505
27. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139: 667-676. doi: 10.1007/s10549-013-2581-3 PMID: 23756627
28. Rathore AS, Kumar S, Konwar R, Srivastava AN, Makker A, Goel MM. (2013) Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50: 239-244. doi: 10.4103/0019-509X.118744 PMID: 24061465
29. Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O,et al. (2014) PD-1+ immune cell infiltration inversely correlates with survival of patients with operable breast cancer. Cancer Immunol Immunother 63(4):395-406. doi: 10.1007/s00262-014-1519-x PMID: 24514954
30. Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T,et al. (2013) FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 1: 625-632. PMID: 24649219
31. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, et al. (2013) Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108: 155-162. doi: 10.1038/bjc.2012.524 PMID: 23169287
32. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, et al. (2011) Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 13: R47. doi: 10.1186/bcr2869 PMID: 21521526
33. Murri AM, Hilmy M, Bell J, Wilson C, McNicol AM, Lannigan A,et al. (2008) The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 99: 1013-1019. doi: 10.1038/sj.bjc.6604667 PMID: 18797461
34. Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A,et al. (2012) Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 7: E44741. doi: 10.1371/journal.pone.0044741 PMID: 23028600
35. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. (2011) Natural killer (NK): Dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 50: 248-254. doi: 10.1007/s12026-011-8231-0 PMID: 21717064
36. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI,et al. (2011) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128: 703-711. doi: 10.1007/s10549-010-1154-y PMID: 20842526
37. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. (2010)Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105-13. doi: 10.1200/JCO.2009.23.7370 PMID: 19917869
38. Hornychova HI, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. (2008) Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26(10):1024-31. doi: 10.1080/07357900802098165 PMID: 19093260
39. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H,et al.Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 132: 793-805. doi: 10.1007/s10549-011-1554-7 PMID: 21562709
40. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 25: 611-618. doi: 10.1093/annonc/mdt556 PMID: 24401929
41. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D,et al. (2013) Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res 73.
42. Lee S, Cho EY, Park YH, Ahn JS, Im YH. (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Onco 52: 73-81.
43. Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R,et al. (2012) Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat 135: 459-467. doi: 10.1007/s10549-012-2132-3 PMID: 22842982
44. Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S, et al. (2009) A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable antitumor response in patients with breast cancer. Oncol Rep 22: 273-278. PMID: 19578766
45. Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y, et al. (2013) Predictive and prognostic factors in locally advanced breast cancer: Effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis 2013; 30: 1047-1062. doi: 10.1007/s10585-013-9602-9 PMID: 23836289
46. Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, et al. (2011) T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 105: 366-371. doi: 10.1038/bjc.2011.261 PMID: 21750556
47. García-Martínez E, Luengo Gil G, Chaves Benito A, González-Billalabeitia E, Vicente Conesa M, García García T,et al. (2014)Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res 16(6):488. doi: 10. 1186/s13058-014-0488-5 PMID: 25432519
48. Heys SD, Stewart KN, McKenzie EJ, Miller ID, Wong SY, Sellar G, et al. (2012) Characterisation of tumour-infiltrating macrophages: Impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat 135: 539-548. doi: 10.1007/s10549-012-2190-6 PMID: 22886449
49. Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 84: 409-421. PMID: 22180678
50. Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA,et al. (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146(1):15-24. doi: 10.1007/s10549-014-2988-5 PMID: 24842267
51. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. (2014) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: RECOMMENdations by an International TILs Working Group 2014. Ann Oncol 26(2):259-71. doi: 10.1093/annonc/mdu450 PMID: 25214542